The European Association of Cardiovascular Imaging/Heart Faiture Association Cardiac Oncology Toxicity Registry : long-term benefits for breast cancer treatment
The European Association of Cardiovascular Imaging/Heart Faiture Association Cardiac Oncology Toxicity Registry : long-term benefits for breast cancer treatment
Bowles EJ, Wellman R, Feigelson HS et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J. Natl Cancer Inst. 104(17), 1293-1305 (2012).
Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97(11), 2869-2879 (2003).
Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin. Cancer Res. 14(1), 14-24 (2008).
Hanrahan EO, Gonzalez-Angulo AM, Giordano SH et al. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J. Clin. Oncol. 25(31), 4952-4960 (2007).
Canto JG, Kiefe CI. Age-specific analysis of breast cancer versus heart disease mortality in women. Am. J. Cardiol. 113(2), 410-411 (2014).
Accordino MK, Neugut AI, Hershman DL. Cardiac effects of anticancer therapy in the elderly. J. Clin. Oncol. 32(24), 2654-2661 (2014).
Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin. Oncol. 25(4 Suppl. 10), 72-85 (1998).
Yeh ET. Cardiotoxicity induced by chemotherapy and antibody therapy. Annu. Rev. Med. 57, 485-498 (2006).
Tan-Chiu E, Yothers G, Romond E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J. Clin. Oncol. 23(31), 7811-7819 (2005).
Lancellotti P, Anker SD, Donal E et al. EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/ HFA COT Registry)-EURObservational Research Program of the European Society of Cardiology. Eur. Heart J. Cardiovascular Imaging 16(5), 466-470 (2015).
Ewer MS, Vooletich MT, Durand JB et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response treatment. J. Clin. Oncol. 23(31), 7820-7826 (2005).
Tarantini L, Gori S, Faggiano P et al. Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: a multicenter cohort analysis. Ann. Oncol. 23(12), 3058-3063 (2012).
Chavez-MacGregor M, Zhang N et al. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J. Clin. Oncol. 31(33), 4222-4228 (2013).
Skovgaard D, Hasbak P, Kjaer A. BNP predicts chemotherapy-related cardiotoxicity and death: comparison with gated equilibrium radionuclide ventriculography. PLoS ONE 9(5), e96736 (2014).
Hahn VS, Lenihan DJ, Ky B. Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies. J. Am. Heart Assoc. 3(2), e000665 (2014).
Kalay N, Basar E, Ozdogru I et al. Protective effects of carvedilol against anthracyclineinduced cardiomyopathy. J. Am. Coll. Cardiol. 48(11), 2258-2262 (2006).
Pituskin E, Haykowsky M, Mackey JR et al. Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101-Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumabmediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. BMC Cancer 11, 318 (2011).
